Introduction
Anaplastic large cell lymphoma (ALCL) expressing ALK (ALK+ ALCL) is a rare but well-defined subtype of peripheral T-cell lymphoma (PTCL). 1 It accounts for approximately 3% of all non-Hodgkin lymphomas (NHL) in adults, 10-15% of pediatric lymphomas and 60-80% of all ALCLs. ALK+ ALCL is hallmarked by various 2p23/ALK chromosomal rearrangements leading to an aberrant expression and constitutive activation of the ALK tyrosine kinase. The most prevalent lesion occurring in more than 80% of ALK+ ALCL is t(2;5)(p23;q35) involving ALK and NPM1 A naplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma is characterized by 2p23/ALK aberrations, including the classic t(2;5)(p23;q35)/NPM1-ALK rearrangement present iñ 80% of cases and several variant t(2p23/ALK) occurring in the remaining cases. The ALK fusion partners play a key role in the constitutive activation of the chimeric protein and its subcellular localization. Using various molecular technologies, we have characterized ALK fusions in eight recently diagnosed anaplastic large cell lymphoma cases with cytoplasmic-only ALK expression. The identified partner genes included EEF1G (one case), RNF213/ALO17 (one case), ATIC (four cases) and TPM3 (two cases). Notably, all cases showed copy number gain of the rearranged ALK gene, which is never observed in NPM1-ALK-positive lymphomas. We hypothesized that this could be due to lower expression levels and/or lower oncogenic potential of the variant ALK fusions. Indeed, all partner genes, except EEF1G, showed lower expression in normal and malignant T cells, in comparison with NPM1. In addition, we investigated the transformation potential of endogenous Npm1-Alk and Atic-Alk fusions generated by clustered regularly interspaced short palindromic repeats/Cas9 genome editing in Ba/F3 cells. We found that Npm1-Alk has a stronger transformation potential than Atic-Alk, and we observed a subclonal gain of Atic-Alk after a longer culture period, which was not observed for Npm1-Alk. Taken together, our data illustrate that lymphomas driven by the variant ATIC-ALK fusion (and likely by RNF213-ALK and TPM3-ALK), but not the classic NPM1-ALK, require an increased dosage of the ALK hybrid gene to compensate for the relatively low and insufficient expression and signaling properties of the chimeric gene. These findings prompted the development of new therapeutic strategies regarding ALK+ tumors. Of particular importance is the recent discovery of specific ALK tyrosine inhibitors, 13, 14 one of which, crizotinib, has proven to have clinical efficacy in the treatment of ALK+ non-small cell lung cancer and ALCL. 15, 16 Herein, we report the molecular characterization of ALK fusions in eight ALK+ ALCL cases exhibiting a cytoplasmic-only ALK staining pattern recently diagnosed in our institution. Intriguingly, all cases analyzed by fluorescence in situ hybridization (FISH) at the time of diagnosis revealed copy number gain of the rearranged ALK gene.
Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC-and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene

Methods
Case selection
Eight cases of ALK+ ALCL with a cytoplasmic-only expression of ALK and available bioarchived material were selected from the database of the Center for Human Genetics and Department of Pathology, University Hospital Leuven, Belgium. Morphology, immunophenotype and clinical records of the reported cases were reviewed. The institutional review board "Commissie Medische Ethiek" of the University Hospital approved this retrospective study and renounced the need for written informed consent from the participants (S56799, ML10896: 12/08/2014).
Cytogenetics and FISH
Conventional Giemsa (G)-banding chromosomal analysis and FISH analysis followed routine protocols. The probes applied on patient material and Ba/F3 cell lines are listed in the Online Supplementary Table S1 . Non-commercial probes were directly labeled with SpectrumOrange-and SpectrumGreen-dUTP (Abbott Molecular, Ottignies, Belgium) by random primed labeling. FISH images were acquired with a fluorescence microscope equipped with an Axiophot 2 camera (Carl Zeiss Microscopy, Jena, Germany) and a MetaSystems Isis imaging system (MetaSystems, Altlussheim, Germany).
Array-based genomic hybridization (aCGH)
Total genomic DNA was isolated from frozen lymphoma samples using standard procedures. High-resolution aCGH was performed using Affymetrix Cytoscan HD, following the manufacturer protocols. Downstream data analysis of copy number alterations was conducted using the software Array Studio, version 6.2.
Cell culture and growth curves
Ba/F3 cells constitutively expressing Cas9 (Ba/F3 Cas9) were generated using a retroviral expression vector containing a Cas9 expression cassette (Online Supplementary Figure S1 ). Ba/F3 Cas9 cells were cultured with interleukin 3 (IL3) in Roswell Park Memorial Institute (RPMI) medium + 10% fetal bovine serum (FBS) before and after electroporation. For growth curves, viability and proliferation were measured on a Guava flow cytometer (Merck Millipore, Darmstadt, Germany) for several consecutive days. 
Quantitative real time polymerase chain reaction (QRT-PCR)
CRISPR/Cas genome editing
Guide (g)RNAs were designed using the Zhang lab's clustered regularly interspaced short palindromic repeats (CRISPR) design tool (Broad Institute of MIT and Harvard, Cambridge, MA, USA) (Online Supplementary Table S3 ). gRNAs were cloned into an expression plasmid (pX321, derived from pX330, Zhang lab; Online Supplementary Figure S2) . Electroporations of Ba/F3 Cas9 cells were carried out using a Gene Pulser Xcell electroporation system (Bio-Rad Laboratories, Hercules, CA, USA). After electroporation, cells were kept in RPMI medium + 10% FBS + IL3 for three days before IL3 depletion was carried out.
Other applied techniques, including the 5' Rapid Amplification of Complementary (c)DNA ends (RACE) PCR, Low Coverage Full Genome Sequencing (LCFGS), Targeted Locus Amplification (TLA) and Nested RT-PCR are briefly described in the Online Supplementary Methods.
Results
Clinical and pathological features
Relevant clinical and pathological features of the reported cases of ALK+ ALCL are shown in Table 1 . There were two children (a 5-year-old boy and a 13-year-old girl) and six adults (two female and four males) ranging from 49 to 78 years of age (mean 64.8 years Supplementary Figure S3 . All cases were CD30 positive, expressed a CD4 + or null cell phenotype in conjunction with variable cytotoxic markers, and overexpressed ALK1 in a strictly cytoplasmic pattern. The stromal infiltrate was prominent in all cases with a variable amount of histiocytes and/or neutrophils.
Cytogenetic and molecular studies
Case 1. Cytogenetic analysis showed a complex karyotype with del(2)(p23) ( Table 2) . FISH with LSI ALK demonstrated a break apart (BA) pattern with the green (5'ALK) signal on del(2)(p23) and two red (3'ALK) signals on a marker chromosome of postulated chromosome 11 origin ( Figure 1A ). Whole chromosome painting proved that der(11) indeed harbors the duplicated fragment of chromosome 2 inserted at 11q. The t(2p23/ALK) rearrangement was further investigated using the 5' RACE PCR approach. The analysis identified an in-frame fusion transcript in which exon 8 of EEF1G, the gene located at 11q12.3, was fused to exon 20 of ALK ( Figure 1B Figure 1C,D) . In addition, the gain of five other regions, loss of three large regions, including that of 9p21.3p24.3/CDKN2A/B, and three microdeletions were detected ( Figure 1C ; Table 1 ). Interestingly, the focal deletion at 8q24.21 covered ~280 kbp sequences flanking the centromeric border of MYC. The loss was confirmed by FISH with LSI MYC; one of two apparently normal looking chromosomes 8 [der (8) ] revealed a significantly diminished red signal ( Figure 1A) .
Case 2. Cytogenetic analysis was unsuccessful. Interphase FISH with LSI ALK showed a BA pattern associated with the gain of up to seven red (3'ALK) signals ( Figure 2A ). The FISH pattern suggested a diploid and tetraploid status of abnormal cells. The ALK rearrangement was further investigated using LCFGS. The analysis identified the RNF213-ALK fusion (supported by at least eight read pairs) whereby exon 8 of RNF213 is fused to exon 20 of ALK, resulting in an in-frame fusion transcript equal to the previously described cases ( Figure 2B ). 6, 17, 18 The fusion and its gain were confirmed by FISH ( Figure  2A) . The performed aCGH analysis demonstrated the ALK-and RNF213-associated gain of 2p23.2p25.3 and 17q23.3q25.3, respectively ( Figure 2C,D) . In addition, aCGH detected the gain of six other regions and loss of three regions, all listed in Table 2 Figure 3A) . Although a number of fused (F), red (R) and green (G) signals in analyzed cells varied, all cases showed a clear predominance of the red signals and variations of the 1F1G3R haematologica | 2017; 102(9) pattern. As a similar pattern was observed in ATIC-ALKpositive lymphoma, 19 we initially examined the status of this gene. FISH with the ATIC BA assay revealed a BA pattern and the presence of extra 5'ATIC signals in all four cases ( Figure 3B ). Subsequent FISH with the 5'ATIC and 3'ALK probes demonstrated three to five fused signals per cell, confirming the ATIC-ALK rearrangement and gain of the chimeric gene in all four cases ( Figure 3C) .
Case 7. The biopsy taken at time of relapse (2016) showed a complex diploid karyotype with a presumed der(1)ins(1;?)(q21;?) and ider(1)(q10) containing a duplicated 1q arm of der(1)ins(1;?)(q21;?) and del(2)(p23) ( Table 2 Figure 3D ). Interphase FISH with LSI ALK revealed the 1F1G3R pattern ( Figure 3E ), as found in ATIC-ALK-positive cases. Considering that the 1q21 breakpoint merges with the localization of TPM3, the known partner of ALK, 6 a possible involvement of this gene was investigated by FISH with the designed TPM3 BA assay (Online Supplementary Table S1 ). Neoplastic cells revealed the 1F3(RsepG) pattern, thus postulating the rearrangement of TPM3 due to ins(1;2)(q21.3;p23p25) ( Figure 3F ). The TPM3-ALK fusion was subsequently confirmed by FISH using the 5'TPM3/3'ALK probes. In the proceeding step, we revised the diagnostic sample (the case was initially misdiagnosed as classical Hodgkin lymphoma), whereby cytogenetic analysis identified rare hypertetraploid cells with i(1)(q10) and del(2)(p23) ( Table 2) . FISH with LSI ALK (Figure 3G ), TPM3 BA ( Figure 3H ) and the 5'TPM3/3'ALK haematologica | 2017; 102(9) probes ( Figure 3I ) demonstrated the presence, at the time of diagnosis (2002), of the TPM3-ALK rearrangement and copy number gain of the ALK fusion.
Case 8. Cytogenetic analysis identified only one abnormal (near tetraploid) metaphase cell harboring five copies of chromosome 2 ( Table 2) . LSI ALK applied on this metaphase cell hybridized with all chromosomes 2: one showed a fused signal and the other four were marked by red signals ( Figure 3J ). The abnormal FISH pattern (1-2F4R) was detected in 11% of interphase cells. Loss of the 5'ALK sequences suggested a focal interstitial del(2)(p23p23) leading to a novel fusion of ALK with a gene located at the centromeric breakpoint of the deletion. To identify a Recurrent gain of ALK in ALK+ ALCL haematologica | 2017; 102 (9) potential partner gene, we used the TLA approach. Unexpectedly, the analysis identified the TPM3-ALK fusion with the breakpoints at the intron 7 of TPM3 and the intron 19 of ALK (Online Supplementary Figure S4) . FISH confirmed the TPM3 rearrangement, which was associated with loss of the 3'TPM3 sequences, and showed that four out of five chromosomes 2 harbor one copy of TPM3-ALK (Figure 3K,L) . Altogether, we identified a cryptic insertion of the 5'TPM3 into the rearranged ALK locus, loss of the 5'ALK and 3'TPM3 sequences, and gain of two copies of TPM3-ALK.
Functional studies
Gain of the EEF1G-, RFN213-, ATIC-and TPM3-ALK hybrid genes found in the present cases contrasts with a constant occurrence of a single copy of NPM1-ALK in t(2;5)-positive ALCL. [20] [21] [22] We hypothesized that ALCLs harboring the variant rearrangements compensate an insufficient expression of the ALK fusions (driven by relatively weak promoters of the partner genes) via an increased dosage of the chimeric gene. To validate this concept, we analyzed expression levels of NPM1, EEF1G, RNF213, ATIC and TPM3 in various normal lymphoid haematologica | 2017; 102(9) cells and T-cell malignancies using previously generated RNA sequencing (Seq) data. 23, 24 The analysis revealed a significantly lower (P-value <0.001) expression of RNF213, ATIC and TPM3 in all samples when compared to NPM1 ( Figure 4A ). In contrast, expression of EEF1G was similar to that of NPM1. Based on these findings, we hypothesized that oncogenic transforming properties of the three variant ALK fusions, RFN213-ALK, ATIC-ALK and Recurrent gain of ALK in ALK+ ALCL haematologica | 2017; 102 (9) 1613 TPM3-ALK, could be lower than the strong NPM1-ALK kinase. To validate our hypothesis, we attempted to generate the Npm-Alk and Atic-Alk fusions in the genome of Ba/F3 cells using CRISPR/Cas9 genome editing. The expression level of Npm1 is around 50-fold higher than the expression level of Atic in this cell line, making it a suitable model to test our hypothesis ( Figure 4B ). We designed a gRNA targeting exon 20 of Alk and gRNAs targeting Npm1 and Atic in regions corresponding to the breakpoints observed in our patient samples ( Figure 4C ). gRNAs targeting Alk and a fusion partner were simultaneously introduced in Ba/F3 Cas9 cells by electroporation. Upon IL3 depletion, both endogenous Alk fusions were able to transform the Ba/F3 Cas9 cells, although cells harboring an endogenous Atic-Alk fusion needed more time to recover from this depletion ( Figure 4D ). In addition to the slower transformation rate, cells harboring an endogenous Atic-Alk fusion presented with a lower growth rate after transformation than cells with an endogenous Npm1-Alk fusion ( Figure 4E ). FISH demonstrated the presence of one copy of the Npm1-Alk and Atic-Alk chimeric genes per cell in the respective cell lines ( Figure 4F ,G).
After keeping the cells in culture for three months, we observed gain of one to three copies of the Atic-Alk fusion gene in approximately 20% of these cells. In contrast, the Npm1-Alk cell line kept a single copy of the chimeric gene in all cells ( Figure 4H ). Altogether, these data demonstrate that the Npm1-Alk fusion is a more potent driver of proliferation than Atic-Alk in Ba/F3 cells, and that the expression level of the fusion partner is a key factor in the transformation potential of the oncogenic fusions.
Discussion
Our study provided evidence that ALCL driven by at least three variant ALK fusions, RNF213-ALK, ATIC-ALK and TPM3-ALK, is characterized by a copy number gain of the ALK hybrid gene. Gain of RNF213-ALK was already observed by us in the previously reported case of ALK+ ALCL, harboring two copies of der(17) t(2;17)(p23.2;q25.3)/RNF213(ALO17)-ALK. 17 Genetic mechanisms underlying the amplification of RNF213-ALK in case 2, however, remain unknown. Notably, the four ATIC-ALK-positive cases presented herein, as well as all reported ATIC-ALK cases documented by FISH, 19, [25] [26] [27] showed extra copies of the chimeric gene. We previously documented that the ATIC-ALK fusion is generated by a pericentric inv(2)(p23q35) and is constantly accompanied by isochromosome 2q [derivative of inv (2)] comprising two extra copies of ATIC-ALK. 19, 25 Based on these data, we presume that the cases reported herein also carry inv(2)(p23q35) and one to three copies of ider(2q). Intriguingly, a similar mechanism of gain of ALK hybrid emerged to underpin the TPM3-ALK rearrangement detected in case 7. The fusion was likely created by the insertion of 3'ALK/2p23p25 at 1q21.3/TPM3 and gained by a subsequent formation of ider(1)(q10). In the second TPM3-ALK-positive case, however, the chimeric gene was produced by a cryptic insertion of 5'TPM3 into the rearranged ALK locus and gained by a duplication of the der(2), as in the case reported by Siebert et al. 28 Notably, one more informative case with TPM3-ALK also presented with two to three copies of the 3'ALK. 29 Lamant et al., 6 who originally described the TPM3-ALK fusion in ALK+ ALCL, linked it to t(1;2)(q25;p23). Considering, however, an opposite transcriptional orientation of both genes, generation of the in-frame TPM3-ALK fusion requires more complicated events, as illustrated in the present and previously reported cases. 28 Altogether, our genetic findings, supported by the published data, 17, 19, [26] [27] [28] [29] highlight a strong association of RNF213-ALK, ATIC-ALK and TPM3-ALK with a copy number gain of the chimeric gene. A spectrum of such ALK fusions is probably broader, but a frequent lack of cytogenetic and/or FISH data hampers their identification. These observations contrast with ALCL driven by NPM1-ALK [20] [21] [22] and at least three variant fusions, CLTC-ALK,
17
TPM4-ALK 30, 31 and TRAF1-ALK, 27, 32 shown to carry a single copy of the ALK hybrid gene. We initially included the novel EEF1G-ALK variant found to be duplicated on der(11) in the former category. Given, however, that two recently published ALCL cases with EEF1G-ALK did not show copy number gain of the ALK fusion gene, 33 duplication of EEF1G-ALK in our case was likely associated with progression of the disease, similar to a case of leukemic ALK+ ALCL with an extra copy of NPM1-ALK. 34 This conclusion is additionally supported by our other data illustrating a strong expression of EEF1G in normal and malignant T cells, similar to that of NPM1. Thus, there is no reason why the EEF1G-ALK fusion gene would require an increased copy number.
In contrast, expression of RNF213, ATIC and TPM3 in lymphoid cells was significantly lower than NPM1 and EEF1G. These findings support the concept that ALCL driven by the RNF213-ALK, ATIC-ALK and TPM3-ALK fusions might require an increased dosage of the ALK chimeric gene to compensate an insufficient expression of ALK in neoplastic cells. To test if the best documented ATIC-ALK fusion is indeed less transforming than the NPM1-ALK fusion, we generated the Npm1-Alk and Atic-Alk fusion genes by inducing Cas9 mediated chromosomal rearrangements in Ba/F3 cells. Growth properties of these engineered cells showed that the transformation potential of Atic-Alk is significantly lower when compared to Npm1-Alk, likely due to a lower expression level of Atic. Interestingly, the tendency of the Atic-Alk-positive Ba/F3 cells to gain extra copies of the Atic-Alk chimeric gene recapitulates the events observed in the original tumors and confirms the selective pressure of the cells to acquire additional copies of the Atic-Alk fusion. We also attempted to generate an endogenous Rnf213-Alk fusion, but since Rnf213 is very lowly expressed in Ba/F3 cells, this fusion could not transform the cells. Tpm3 was not included in the functional studies, since it was only recently added to the study. Of note, Giuriato et al. 35 previously showed that in conditional knock-in mice both TPM3-ALK and NPM1-ALK could induce B-cell lymphoma/leukemia with a similar disease latency. In these transgenic mice, however, the expression levels of both ALK fusions were similar, since their expression was driven by an external promoter. This could explain the observed equal tumorigenic potential of both ALK fusions.
The novel EEF1G-ALK fusion which we identified in a child with ALK+ ALCL extends the already long list of ALK fusion partners comprising approximately 20 genes. 7 The very recent report of two pediatric patients with EEF1G-ALK 33 indicates that the fusion is recurrent and strongly associated with pediatric ALK+ ALCL. EEF1G, located at 11q12.3, has 10 exons encoding for an eukaryotic translation elongation factor 1γ. Together with α, β and δ subunits, it forms the eukaryotic elongation factor complex, which is predominantly involved in protein biosynthesis with an elongation of the polypeptide chains. 36, 37 EEF1G comprises a glutathione-S-transferase (GST)-like N-terminal domain and a C-terminal (CT) domain. 37 Although all four subunits of the elongation factor complex are highly expressed in most eukaryotic cells, the role of human EEF1G is poorly understood. Notably, an increased expression of EEF1G has been detected in various human carcinomas. [37] [38] [39] [40] It has been suggested that overexpression of EEF1G stimulates the overgrowth of neoplastic cells. 41 In the present case of ALK+ ALCL, exons 1 to 8 of EEF1G are fused to exon 20-29 of ALK, resulting in a chimeric protein with the complete GST-like N-terminal domain and part of the CT domain of EEF1G, fused to the complete intracellular protein tyrosine kinase (PTK) domain of ALK ( Figure 2B ). Even though the complete PTK domain is involved, the ALK fragment contains the final 513 amino acids, which is shorter in comparison to the fragment involved in most other ALK fusions, containing the final 563 amino acids. 42 Of note, both cases reported by Palacios et al. 33 revealed breakpoints within intron 7 of EEF1G and intron 20 of ALK. As the fusions were identified by RNA-Seq, genetic mechanisms underlying these rearrangements are unknown.
The postulated t(2;11)(p23;q12.3), however, is unlikely due to an opposite transcriptional orientation of both genes, similar to TPM3 and ALK. Functional studies performed by the authors provided evidence of the dimerization properties of the EEF1G-ALK fusion, constitutive activation of ALK kinase and its strong oncogenic potential similar to that of NMP1-ALK.
Our patient with EEF1G-ALK experienced an unfavorable and fatal clinical course. Although ALK+ ALCL has a relatively good prognosis, chemoresistant and aggressive forms of this lymphoma, recurrently featured by MYC aberrations, have been recurrently reported. 32, [43] [44] [45] Notably, our case displayed a microdeletion neighboring MYC and loss of CDKN2A/B at 9p21, a known poor prognostic factor in tumors. 46 We presume that a focal del(8)(q24q24) could activate MYC by loss of negative regulatory elements upstream of the gene, for example. Although clinical data of the EEF1G-ALK-positive cases reported by Palacios et al. 33 are not available, we believe that an aggressive clinical course and unfavorable prognosis of certain ALK+ ALCL is not determined by the type of ALK fusion, but rather by secondary hits affecting potent oncogenes and tumor suppressor genes (e.g., MYC, TP53, PRDM1 and CDKNA2/B). 32, 44, 45, 47 In summary, we investigated eight recently diagnosed cases of ALK+ ALCL with a cytoplasmic-only expression of ALK and identified one novel EEF1G-ALK rearrangement and three already known fusions, RNF213-ALK, TPM3-ALK and ATIC-ALK. Occurrence of the latter rearrangement in four out of eight (50%) of the cases studied confirms that ATIC-ALK is the most prevalent variant fusion in ALK+ ALCL. Importantly, RNF213-ALK, TPM3-ALK and ATIC-ALK fusions were recurrently present in two or more copies, contrasting with the NPM1-ALK chimeric gene which constantly occurs in one copy. Our functional studies show that ALK+ ALCL driven by ATIC-ALK compensates the weak expression and possibly weak oncogenic properties of this variant ALK fusion by an increased gene dosage. We propose a similar explanation for the copy number gain of RNF213-ALK and TPM3-ALK. Altogether, our findings support the hypothesis that the transforming capacities of ALK fusions depend on the biological features of the partner genes. 48 
